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Abstract: Approximately a third of patients with newly diagnosed
non-small cell lung cancer (NSCLC) have locally or regionally
advanced disease not amenable for surgical resection. Concurrent
chemoradiation is the standard of therapy for patients with unresect-
able locally advanced NSCLC who have a good performance status
and no significant weight loss. Prospective studies conducted over
the past two decades have addressed several important questions
regarding systemic therapy and thoracic radiation. They include the
role of induction/consolidation chemotherapy, integration of newer
chemotherapy agents with radiation and the impact of molecularly
targeted agents. Improved radiation therapy techniques and precise
targeting of the tumors have played a key role in this setting.
Moreover, it has been shown that higher than conventional doses of
thoracic radiation can be administered safely in combination with
chemotherapy. This review will discuss these issues in detail and
outline the strategies that need to be employed to improve the
outcomes in patients with locally advanced NSCLC.
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Approximately one third of patients with non-small celllung cancer (NSCLC) are diagnosed with locally or
regionally advanced unresectable disease at presentation.
Combined modality therapy with chemoradiation is the stan-
dard of care for patients with unresectable locally advanced
NSCLC who have a good performance status and no signif-
icant weight loss. There is no universally agreed definition of
“unresectable locally advanced NSCLC.” Many physicians
would consider patients with primary tumors involving major
blood vessels and vertebral body or those with multistation
mediastinal lymph node involvement to have unresectable
locally advanced NSCLC. Prospective clinical trials con-
ducted over the past three decades have firmly established the
beneficial role of chemotherapy and radiation over radiation
alone in this disease. The progress has been slow; nonethe-
less, the 3-year survival rate has steadily increased from less
than 10% to over 25% in some trials over the past thirty
years.1 Although some of the improvement could be attrib-
uted to refined and improved staging chiefly secondary to the
widespread use of fluorine-18 (F-18) dexoyglucose positron
emission tomography (FDG-PET), advances in radiation
therapy planning and improved delivery of chemotherapy
certainly have contributed to the modest success. Disappoint-
ingly, recent studies have demonstrated no improvement in
survival with the use of docetaxel consolidation therapy after
concurrent chemoradiation and detrimental effect with the
addition of gefitinib maintenance therapy. This conceptual
review will summarize briefly the seminal studies conducted
in the past two decades, address the current areas of research
and explore potential avenues for future research.
PROGNOSTIC FACTORS IN PATIENTS WITH
LOCALLY ADVANCED NSCLC
Locally advanced stage III NSCLC comprises a heter-
ogeneous group even if one applies the readily available
demographic and clinical features without considering the
inherent and as yet poorly defined biologic characteristics.2
These clinical characteristics include number of nodes and
nodal stations involved, size of primary tumor, baseline
pulmonary function, gender, presence or absence of signifi-
cant weight loss, and performance status. Patients with mi-
croscopic N2 disease involving a single station or two sta-
tions have a better outcome than those with contralateral or
supraclavicular lymph node (N3) involvement.2 In a prospec-
tive study of 203 patients with locally advanced NSCLC, 10
prognostic factors including age, sex, ethnicity, smoking
status, performance status, body mass index, forced expira-
tory volume in 1 minute (FEV1), use of baseline FDG-PET
scan, stage (IIIA versus IIIB), and baseline hemoglobin were
analyzed to find out the factors associated with better out-
comes.3 In a multivariate analysis, baseline hemoglobin (12
g/dl) and FEV more than 2 L predicted favorable outcomes in
patients treated with chemoradiation. Apart from known
clinical characteristics, molecular aberrations very likely play
an important role in determining outcomes and responses to
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chemotherapy and radiation. Global genomic studies have
correlated signature patterns associated with poor outcomes
in patients with resected NSCLC.4,5 Moreover, resistance to
platinum agents has been associated with expression levels of
key proteins involved in DNA repair.6,7 Although no such
studies have been done exclusively in patients with unresect-
able locally advanced NSCLC, it is likely that such an
approach could potentially identify those with inherently
unfavorable biology and those who are unlikely to respond to
platinum based therapy.
CHEMOTHERAPY ISSUES IN STAGE III NSCLC
Several prospective studies conducted over the past two
decades have clearly demonstrated the superiority of concur-
rent chemoradiation over sequential chemotherapy followed
by radiation in patients with locally advanced NSCLC who
have a good performance status and no significant weight loss
(Table 1).1,8–14 However severe toxicities (chiefly esopha-
geal) associated with concurrent chemoradiation are more
commonly seen than with sequential chemotherapy followed
by radiation. Clinical trials conducted over the past several
years have addressed some important questions with regard to
systemic therapy. They include the role of consolidation
chemotherapy after concurrent chemoradiation, use of induc-
tion chemotherapy administered before concurrent chemora-
diation, the optimal strategy for using chemotherapy (radi-
osenitizing low dose versus systemically active dose) in
conjunction with radiation and finally the role of molecularly
targeted agents in the treatment of locally advanced NSCLC.
Consolidation Chemotherapy
Because administration of docetaxel improves survival
over best supportive care for patients with progressive disease
after initial treatment with platinum based chemotherapy, a
phase II study was conducted by the Southwest Oncology
Group (SWOG) to test the efficacy of docetaxel as consoli-
dation therapy in patients with locally advanced NSCLC after
treatment with concurrent cisplatin, etoposide, and thoracic
radiation.15 This study reported an impressive median sur-
vival of 26 months and a 5-year survival of 29% in 83
patients with stage III B NSCLC. These results seemed
particularly striking when compared with SWOG’s historic
control from a similar study (with cisplatin/etoposide consol-
idation) where the median survival was only 15 months and
a 5-year survival of 15%.16 A randomized study conducted by
the Hoosier Oncology Group (HOG) enrolled 203 patients
with locally advanced NSCLC to cisplatin, etoposide, and
thoracic radiation and randomized 147 patients who com-
pleted chemoradiation to observation or three cycles of con-
solidation docetaxel.17 The study was closed prematurely
following a planned interim futility analysis conducted by the
Data Safety Monitoring Board. The overall median survival
for the entire population of 203 patients was 21 months.
Addition of docetaxel did not improve overall survival (pri-
mary end point) or progression free survival. However treat-
ment related severe toxicities (chiefly neutropenic fever and
pulmonary toxicities) were predictably higher with docetaxel
compared with observation alone. Consequently, docetaxel
consolidation was associated with more treatment related
death associated (5%) than with observation alone (0%, p 
0.058). A preliminary analysis of the population studied by
SWOG and HOG failed to identify any clinical or demo-
graphic features that could have accounted for the disappoint-
ing results seen with docetaxel consolidation in the HOG trial
(Table 2). The eligibility criteria between the SWOG and
HOG studies differed significantly with regard to pulmonary
function tests. However, analysis of the outcomes in the HOG
TABLE 1. Select Phase III Trials Assessing Chemoradiotherapy
Study n Therapy
Median
Survival p
Toxic Effects
Esophagitis
(grade 3)
Pneumonitis
(grade 3)
Furuse et al.14 314 (C) MVP  2/TR 16.5 mo 0.039 4% 2%
(S) MVP  2 3 TR 13.3 mo 4% 2%
Currran et al.13 400 (C) PVbl  2/TR 17 mo 0.046 25% 4%
(S) PVbl  2 3 TR 14.6 mo 4% 7%
Fournel et al.12 205 (C) PE/TR 3 PVr  3 16.3 mo NS 32% 5%
(S) PVr  3 3 TR 14.5 mo 3% 11%
Clamon et al.11 283 (C) PVbl  2 3 Cb/TR 13.4 mo NS 12% 4%
(S) PVbl  2 3 TR 13.5 mo 4% 8%
Huber et al.10 214a (C) TCb  2 3 TCb/TR 18.7 mo NS 13% 0%
(S) TCb  2 3 TR 14.1 mo 6% 0%
Zatloukal et al.9 102 (C) PVr  1 3 PVr/TR 16.6 mo 0.023 18% 4%
(S) PVr  4 3 TR 12.9 mo 4% 2%
Gervais et al.8 163b (C) PVr  2 3 Cb/TR 14 mo NS 4% —
(S) PVr  2 3 TR 11 mo 3.5% —
a Patients randomized after induction chemotherapy.
b Primary endpoint local control at 1-yr.
TR, thoracic radiotherapy; C, concurrent therapy; S, sequential therapy; MVP, cisplatin/vindesine/mitomycin; PVbl,
cisplatin/vinblastine; PVr, cisplatin/vinorelbine; Cb, carboplatin; PE, cisplatin/etoposide; TCb, paclitaxel/carboplatin.
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study based on the pulmonary function test criteria did not
reveal survival differences between those who had lower
FEV1 (2 L) or higher FEV1. Based on the results of the
HOG study, use of consolidation chemotherapy is not a
current evidence-based standard of care. At the same time it
remains counterintuitive that the optimal number of cycles in
stage IV NSCLC is currently defined as 4, whereas in stage
III disease only two cycles given during radiotherapy provide
maximum therapeutic effect.
Induction Therapy
CALGB conducted a phase III study (CALGB 39801)
that randomized 366 patients with locally advanced NSCLC
to concurrent chemotherapy (low dose paclitaxel and carbo-
platin weekly) with thoracic radiation or the same regimen
administered after two cycles of induction chemotherapy
(paclitaxel and carboplatin for two cycles in systemically
active doses).18 Addition of induction chemotherapy to con-
current chemoradiation did not improve survival (p  0.3).
Outcomes were poor in both the groups with median overall
survival of only 12 months without induction therapy and 14
months with induction therapy. Addition of induction che-
motherapy did not improve the outcomes. Similar results
were observed in a prospective study that randomized 134
patients with locally advanced NSCLC to induction therapy
(with two cycles of gemcitabine and cisplatin) followed by
concurrent chemoradiation (weekly paclitaxel and cisplatin)
or concurrent chemoradiation alone with weekly paclitaxel
and cisplatin.19 The median overall survival with induction
followed by concurrent chemoradiation was 12.6 months
(95% CI: 8.6–16.7 months) and with concurrent chemoradia-
tion alone was 18.2 months (95% CI: 11.7–24.8 months, p 
0.18). Based on these two studies that directly addressed the
issue of induction therapy, we do not recommend the use of
induction chemotherapy before concurrent chemoradiation in
routine clinical practice.
The CALGB 39801 study brought to the forefront the
issue of the optimal strategy for chemotherapy (systemically
active doses of chemotherapy or the so called “low dose”) to
be used in conjunction with radiation therapy. An argument
for systemically active doses of chemotherapy can be made as
the majority of the relapses in patients with locally advanced
NSCLC occur at distant sites presumably because of the
presence of micrometastatic disease at presentation. Further-
more, it is worth reflecting that progress made in the treat-
ment of locally advanced esophageal cancer and limited stage
small cell lung cancer have been achieved through the use of
systemically active doses of chemotherapy in conjunction
with radiation. Some of the best results in the treatment of
locally advanced NSCLC have been reported when chemo-
therapy was administered in doses that could be considered to
be systemically active.15,17,20,21 Administration of systemi-
cally active doses has the potential to eradicate micrometa-
static disease that is almost universally present in stage III
NSCLC. Although no prospective randomized studies have
compared so called “low dose” chemotherapy with “full
dose” chemotherapy with thoracic radiation to the best of our
knowledge, in general, median overall survival reported with
the latter strategy has consistently exceeded 17 months.
Future attempts should be made to optimize systemic therapy
that can be safely administered in conjunction with thoracic
radiation therapy.
The Locally Advanced Multimodality Protocol (LAMP)
compared sequential chemotherapy followed by radiation
with two experimental regimens, one that employed induc-
tion chemotherapy followed by concurrent chemoradiation
(induction regimen) and another, concurrent chemoradiation
followed by consolidation chemotherapy (given at systemi-
cally active doses) with the same doublet chemotherapy
(consolidation regimen).22 Chemotherapy in this study con-
sisted of paclitaxel and carboplatin. The median survival of
the consolidation regimen was 16.3 months compared with
13 months with the sequential approach (control group) and
12.7 with the induction approach. Concurrent chemoradiation
followed by consolidation was associated with a greater
incidence of severe toxicities than the other two approaches.
This randomized phase II study was not adequately powered
to answer which of the two experimental regimens was
superior to the (then) control regimen of sequential chemo-
therapy followed by radiation. Notably, the LAMP study did
not compare concurrent chemoradiation followed by consol-
idation with concurrent chemoradiation alone.
RADIATION THERAPY OPTIMIZATION IN
STAGE III NSCLC
Therapeutic gains in the treatment of locally advanced
NSCLC have been generally attributed to the integration of
systemic chemotherapy with thoracic radiotherapy. For ex-
ample, 4 of 24 phase III North American Cooperative Group
Trials conducted between 1970 and 1998 demonstrated a
benefit for the experimental arm, and all studied the addition
of cisplatin based chemotherapy to thoracic radiotherapy.23
That said, the last decade and a half has brought major
advances in the technology available for tumor imaging,
TABLE 2. Consolidation Therapy with Docetaxel
Study SWOG 950415 HOG 01–2417 SWOG 002319
No. of patients 83 203 571
Median age 60 (34–80) 63 61 (20–83)
Proportion of women 27% 34% 31%
FEV-1 2 100% 47% 73%
RT dose 61 Gy 59.4 Gy 61 Gy
Febrile neutropenia
(G3/4)
During chemodRT NR 10% 5%
During consolidation 9% 11% 5%
Esophagitis (G3/4)
During chemo-RT 17% 17% 14%
Pneumonitis (G3/4) 7% 8% —
Treatment related death 5% 5% 6%
Median survival (mo) 26 mo 21.1 moa 19b
a Median survival with observation vs. docetaxel consolidation, 24.1 and 21.5 mos,
respectively (p  0.940).
b Median and overall survival includes patients who received gefitinib or placebo.
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radiotherapy treatment planning and the delivery of tho-
racic radiotherapy. Coupled with an evolving philosophy
of target determination, these changes have resulted in
several single arm trials assessing intensive thoracic radio-
therapy doses, and phase III trials comparing thoracic
radiotherapy regimens have recently been initiated. As
technology continues to rapidly evolve, it will be critical to
demonstrate that integration of these efforts into routine
practice results in an improved therapeutic ratio, either by
improving tumor control or reducing the toxic effects of
therapy.
Dose
Although thoracic radiotherapy is recognized as an inte-
gral component therapy in locally advanced NSCLC, there is no
established (e.g., level 1 evidence) standard thoracic radio-
therapy regimen. A phase III trial initiated by the Radiation
Therapy Oncology Group (RTOG) in the 1970s, RTOG
73-01, is often cited as the seminal work assessing thoracic
radiotherapy dose regimens for locally advanced NSCLC.24
This trial randomized patients to receive continuous daily
fractionation thoracic radiotherapy to a total dose of 40, 50, or
60 Gy, or to receive 40 Gy in 4 Gy fractions with a planned
2-week interruption. The group receiving 60 Gy continuous
daily fractionation experienced the best short-term survival,
although the 5-year survival, approximately 5%, was equally
poor in all cohorts. Although 60 Gy conventionally fraction-
ated thoracic radiotherapy has been accepted as standard of
care, the relevance of this trial to current practice is further
muddied by the use of radiotherapy fields and techniques that
are no longer considered acceptable. Moreover, careful as-
sessment following standard thoracic radiotherapy demon-
strates residual local tumor in more than 80% of cases.25
Several dose escalation trials have been conducted
since the introduction of conformal three-dimensional radio-
therapy (3D-chemoradiotherapy) planning. The 3D-chemora-
diotherapy era allows for increased confidence in treatment
planning through more accurate definition of tumor volumes
and normal tissues as well as improved tools for visualizing
dose distributions surrounding these structures. Initial 3D-
chemoradiotherapy trials aimed to increase dose by adding
fractions of conventional thoracic radiotherapy. Trials from
Memorial Sloan Kettering Cancer Center, Washington Uni-
versity, the University of Michigan and the University of
Chicago demonstrated that modest dose escalation, in the
range of 70 Gy, could be safely achieved.26–28 A larger
prospective phase I dose escalation trial conducted at the
University of Michigan assigned patients into dose escalation
“bins” based on the volume of irradiated lung.29 Target
volumes included the primary tumor and lymph nodes more
than 1 cm on computed tomography (CT). Sixty-nine patients
had stage III NSCLC and 28 stage I/II NSCLC. Approxi-
mately 25% of patients received neoadjuvant chemotherapy.
The maximum-tolerated dose was only established for the
largest bin, at 65.1 Gy, whereas dose escalation as high as
102.9 Gy was achievable for limited lung volumes. The
median survival for patients with stage III or locally recurrent
disease was 16 months, with 3-year survival of 14%.30 A
multi-institutional phase I/II three-dimensional radiation ther-
apy dose escalation trial including 177 patients has been
reported by the RTOG.31 Neoadjuvant chemotherapy was
allowed. Similar to the Michigan trial, patients were stratified
at escalating radiation dose levels according to the calculated
risk of pneumonitis. The percentage of total lung volume
receiving in excess of 20 Gy (V20) was used to determine
group assignments. The maximum tolerated dose was 83.8
Gy for patients with V20 of less than 25% and 77.4 Gy for
those with V20 of 25 to 36%. Accrual to a third arm treating
larger lung volumes was unsuccessful. Local control at 2
years ranged from 50 to 78%, and median overall survival
ranged from approximately 12 to 16 months (estimated from
survival curve) in stage III disease.
Given the impact of phase III trials demonstrating the
superiority of combined modality therapy for stage III
NSCLC, recent studies have assessed high dose thoracic
radiotherapy delivered concurrent with chemotherapy (Table
3).13 Rosenman reported a phase I/II trial from the University
of North Carolina. Sixty-two stage III NSCLC patients were
treated with two cycles of induction carboplatin/paclitaxel
chemotherapy followed by concurrent weekly carboplatin/
paclitaxel with radiation doses escalated from 60 to 74 Gy
with conformal three-dimensional planning.32 The median
survival and 3-year survival rates were 24 months and 38%,
respectively. Toxicity was modest. The results of a confir-
matory phase II trial cooperative group study assessing 74 Gy
conformal thoracic radiotherapy, CALGB 30105, were re-
cently reported and once again an encouraging median sur-
vival of 24 months was observed for patients receiving
concurrent (plus induction) carboplatin and paclitaxel.33
CALGB 30105 also included a treatment arm assessing
gemcitabine/carboplatin induction chemotherapy and twice-
weekly gemcitabine during thoracic radiotherapy which was
closed early because of excessive pulmonary toxicity. Con-
temporaneous phase I thoracic radiotherapy dose escalation
trials from the RTOG and North Central Cancer Treatment
Group (NCCTG) evaluated conformal thoracic radiotherapy
concurrent with carboplatin and paclitaxel.34,35 The maxi-
mum tolerated dose from each trial was 74 Gy in 2 Gy
fractions. A phase III Intergroup Study (RTOG 0617/NCCTG
N0628/CALGB 30609) comparing thoracic radiotherapy
dose (60 Gy versus 74 Gy) has now been activated to help
define the impact of radiotherapy dose in the context of
concurrent chemotherapy.36 In the meantime, the appropriate
thoracic radiotherapy dose remains unclear, as witnessed in
part by the range of thoracic radiotherapy doses employed in
North American cooperative group Studies. An assessment of
thoracic radiotherapy dose across protocols is confounded by
the use of varying selection criteria, chemotherapy regimens,
and schedules and timing/sequencing of thoracic radiotherapy
as shown in Table 4.13,15,17,18,20,37
Fractionation
An alternative approach to enhancing outcomes
through thoracic radiotherapy modulation is to increase the
biologic intensity of therapy by accelerating the time to
complete treatment, often by delivering multiple daily treat-
ments. It is worth noting that several randomized trials have
demonstrated no benefit for hyperfractionated radiotherapy if
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the treatment course is not accelerated.13,38,39 Experimental
and clinical experience suggest that accelerating the radio-
therapy course may lead to improved tumor control, perhaps
by allowing less opportunity for tumor repopulation during
treatment, and retrospective evidence suggests a detrimental
effect of prolonging the time to complete thoracic radiother-
apy delivery in NSCLC.40 Accelerating the treatment course
has resulted in improved clinical outcomes in both locally
advanced NSCLC and limited small cell lung cancer.41,42 The
United Kingdom trial of continuous hyperfractionated accel-
erated radiotherapy (CHART), 54 Gy in 36 fractions of 1.5
Gy over 12 consecutive days, demonstrated improved sur-
vival for CHART compared with conventional thoracic ra-
diotherapy.43 Acute dysphagia was more frequent with
CHART compared with conventional radiotherapy, but no
other differences in toxicity were noted. The Eastern Coop-
erative Oncology Group attempted to test an “Americanized”
version of CHART, which eliminated therapy during week-
ends (HART). This phase 3 trial, which randomized patients
to standard thoracic radiotherapy or HART after completing
two cycles of carboplatin and paclitaxel chemotherapy,
closed early because of slow accrual. Median survival was
20.3 months for HART compared with 14.9 months with
standard thoracic radiotherapy, but the difference did not
reach statistical significance.37 Nevertheless, the results in the
HART cohort compare favorably to trials of simultaneous
chemoradiotherapy and again point to the promise of thoracic
radiotherapy dose intensity.
TABLE 3. North American Cooperative Group Studies of Chemotherapy Concurrent with High Dose (70 Gy) Thoracic
Radiotherapy
Study n
TR Dose
(dose per fraction)
Concurrent
Chemotherapy Additional Chemotherapy
Median
Survival
Acute Toxic
Effects
CALGB 3010532
(phase II)
37 74 Gy (2 Gy) Carboplatin 
Paclitaxel
Carboplatin  Paclitaxel
(induction)
24 mo 3% grade 5
17% grade 3 
esophagitis
14% grade 3 
pulmonary
23a 74 Gy (2 Gy) Gemcitabine Carboplatin  Gemcitabine
(induction)
12.5 mo 8% grade 5
36% grade 3 
esophagitis
37% grade 3 
pulmonary
RTOG 011733
(phase I/II)
45b 74 Gy (2 Gy)b Carboplatin 
Paclitaxel
Optional (adjuvant) Recently
completed
accrual
Recently completed
accrual
NCCTG34
(phase I)
13 70–78 Gy (2 Gy) Carboplatin 
Paclitaxel
Carboplatin  Paclitaxel
(adjuvant)
NS No grade 5 toxic
events
Maximum tolerated
dose  74 Gy
CALGB 3040772
(phase II)
100 70 Gy (2 Gy) Pemetrexed 
Carboplatin
Pemetrexed (adjuvant) Recently
completed
accrual
No data available at
the present time
a Arm closed early because of toxic events.
b Phase II cohort.
TR, thoracic radiotherapy; NS, not specified.
TABLE 4. Variation in Standard TR Dose in Phase III Cooperative Group Studies for Locally Advanced NSCLC
Study n
TR Dose
(dose per fraction)
Concurrent
Chemotherapy
Additional
Chemotherapy
Overall Survival
Median 2-yr
RTOG 941013 201 63 Gy (1.8 Gy) Cisplatin  Vinblastine — 17.1 mo 37%
CALGB3980118 184 66 Gy (2.0 Gy) Carboplatin  Paclitaxel Carboplatin  Paclitaxel
(induction)
14 mo 31%a
HOG LUN01-2417 203 59.4 Gy (1.8 Gy) Cisplatin  Etoposide With or without Docetaxel
(adjuvant)
21.1 mo 42%b
ECOG 259736 59c 64 Gy (2.0 Gy) — Carboplatin  Paclitaxel
(induction)
14.9 mo 24%
SWOG 002319 571 61 Gy (1.8 Gy 
2 3 2.0 Gy  6)
Cisplatin  Etoposide Docetaxel with or without
Gefitinib (adjuvant)
19 mo 42%
a Eligibility includes patients with more than 5% weight loss.
b Estimated from survival curve.
c Only includes patients randomized to standard TR after completing induction chemotherapy.
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Few trials have documented the safety of hypofraction-
ated radiotherapy given simultaneously with chemotherapy
for locally advanced NSCLC. Target volumes may be too
large to allow sufficient protection of surrounding normal
structures (e.g., lung and esophagus) despite the use of
conformal techniques. RTOG L0117 was initiated with the
goal of establishing the maximum tolerated dose of radio-
therapy, in terms of Gy per fraction that can be delivered
using 3D-chemoradiotherapy and concurrent paclitaxel and
carboplatin chemotherapy. Despite the requirement for strict
normal tissue limits (e.g., total lung V20 30%), the initial
schedule, 75.25 Gy in 2.15 Gy per fractions, was not accept-
able because of dose limiting pneumonitis.35 Whether newer
treatment techniques, including intensity modulated radio-
therapy (IMRT), helical tomotherapy, or stereotactic body
radiotherapy can result in safe hypofractionation in stage III
disease is under investigation.44
Treatment Planning and Target Determination
Conformal radiotherapy planning is now routinely in-
tegrated into clinical practice throughout the United States.45
Even in the absence of dose escalation, 3D-chemoradiother-
apy has the potential to widen the therapeutic window by
reducing normal tissue toxicity and by ensuring the CT-based
planning volume is appropriately dosed. For instance, quality
assurance reviews in the era of 2D planning demonstrate
geographic tumor miss in approximately one fifth of pa-
tients.46 Although interobserver variability is common in
defining the target volumes used in conformal planning for
lung cancer, the risk of actually missing gross tumor should
be minimal if 3D tools are applied appropriately. 3D-chemo-
radiotherapy technology has allowed markedly increased
doses for NSCLC, but prospective trials have generally in-
cluded select patients, and treatment dose has often been
tailored to the individual’s calculated risk of toxicity. Further
confounding the interpretation of prospective 3D dose esca-
lation trials is the incorporation of tissue heterogeneity cor-
rections in some, but not all, trials. There is now general
agreement among the North American cooperative groups
that heterogeneity corrections will be routinely employed in
future studies. Implementation of IMRT may allow for im-
proved thoracic radiotherapy dose conformality with im-
proved tumor coverage and better protection of normal struc-
tures.47,48 The complexity of administering IMRT in the
thorax, given the sharp dose fall-off coupled with issues of
tissue heterogeneity and tumor motion, needs to be empha-
sized. The National Cancer Institute only recently allowed
IMRT in North American cooperative groups lung cancer
studies, and IMRT may only be used after stringent institu-
tional credentialing including documenting the institution’s
ability to control respiratory motion to a maximum excursion
of 1.0 cm.
The philosophy regarding appropriate target volumes in
locally advanced NSCLC has evolved, particularly in regard
to the inclusion of clinically uninvolved draining hilar and
mediastinal lymph nodes. The major drawback of elective
nodal irradiation (ENI) is the incorporation of larger lung
volumes in the radiotherapy field, which may limit thoracic
radiotherapy intensification, and the pros and cons of ENI
have been widely debated.49,50 Although most of prospective
trials have included ENI, recent dose escalation studies from
the RTOG and NCCTG have not included ENI.34,35 Interest-
ingly, the University of North Carolina thoracic radiotherapy
dose escalation study mandated ENI, although CALGB
30105 allowed treatment of limited clinically uninvolved
lymph nodes.32,33 Omission of ENI has not been associated
with a substantial risk of isolated regional nodal failure.
Rosenzweig et al. reported the Memorial Sloan-Kettering
3D-chemoradiotherapy experience for 171 patients with stage
I–IIIB NSCLC.51 ENI was not given, although 122 of 171
patients had lymph node staging through mediastinoscopy or
thoracotomy. Overall, only 11 patients (6.4%) with elective
nodal failure were identified, including 1% ipsilateral supra-
clavicular, 3% contralateral supraclavicular, 4% ipsilateral
inferior mediastinal, and 1% contralateral inferior mediastinal
failure rates. Reports from additional 3D-chemoradiotherapy
trials confirm the low risk of isolated failures in untreated
nodal regions52,53 and a published analysis of 1705 patients
treated on RTOG NSCLC trials failed to support the use of
ENI.54 In this study, the adequacy of ipsilateral hilar coverage
correlated with in-field progression but did not influence
survival. Coverage in the mediastinum, ipsilateral supracla-
vicular area and contralateral hilum did not correlate with
tumor progression or survival. The preliminary results of a
randomized prospective study from China, comparing in-
volved-field thoracic radiotherapy with or without ENI,
were recently reported.55 Pulmonary toxicity was observed
more frequently in patients treated with ENI (39% versus
17%), while 3-year overall survival favored the group
treated with involved-field thoracic radiotherapy alone
(19.2% versus 27.3%).
The integration of functional imaging with FDG-PET
for radiotherapy treatment planning is an important advance
that will further mitigate the potential impact of ENI in
locally advanced NSCLC. PET imaging may also refine
radiotherapy target volumes by displaying the extent of “ac-
tive” disease, including differentiating tumor from postob-
structive atelectasis. Moreover, FDG-PET can help select
patients who are not appropriate candidates for radical tho-
racic radiotherapy. In an Australian trial including 100 pa-
tients with clinical stage III NSCLC, 24% of patients were
upstaged following FDG-PET imaging.56 In another study of
30 patients with locally advanced NSCLC, only 23 were still
considered candidates for radical therapy.57 FDG-avid nodes,
which were not apparently involved by CT criteria, were
observed in 5 of these 23 patients. Moreover, FDG-PET
information led to a change in target definition in as many as
three-quarters of all cases, although this varied heavily ac-
cording to the treating physician. In a prospective study from
Washington University, FDG-PET findings altered the Amer-
ican Joint Committee on Cancer TNM stage in 8 of 26
patients undergoing evaluation for definitive radiotherapy.58
PET altered the radiotherapy target volumes in greater than
half of patients planned with 3D-chemoradiotherapy. An
ongoing multicenter prospective study, RTOG 0515, has a
primary objective of determining the impact of PET/CT
fusion for each patient by comparing gross tumor volume
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contours and 3D-chemoradiotherapy treatment plans using
two separate data sets (PET/CT and CT only).
Reproducibility of patient positioning is mandatory to
maximize the therapeutic index. Immobilization is generally
provided through the use of custom molded foam cradles,
vacuum-locked bags, or thermoplastic sheets. Once the pa-
tient is appropriately immobilized, efforts can focus on ac-
counting for internal tumor motion. Tumor movement during
respiration may be substantial in the cranial-caudal, anterior-
posterior and lateral direction, leading to inadequate tumor
coverage.59,60 Classically, the radiation field has been ex-
tended based upon observation under fluoroscopic imaging,
but technology now is available to perform four-dimensional
CT (4D-CT) scans, which account for several defined phases
of breathing. 4D-CT scans allow determination of tumor
motion for determining the internal target volume, and also
can be used in concert with respiratory gating systems that
can be programmed to activate the linear accelerator (beam-on)
only during specific predefined phases of the respiratory
cycle.61 Other strategies to account for tumor motion include
the use of modified breathing techniques and the placement of
abdominal compression devices to diminish the amplitude of
the respiratory cycle.62,63 Some of these techniques may be
cumbersome for patients with pulmonary dysfunction, and
can markedly increase total treatment time. More advanced
solutions, including true 4-D solutions that can accurately
track tumor motion and adapt with real-time changes in the
radiation field, are currently under investigation.64 The recent
introduction of image-guided radiotherapy (IGRT) is a major
advance that facilitates treatment accuracy by obtaining either
a (cone-beam) CT scan or kV images of the region of interest
before each radiotherapy treatment.65 IGRT images are then
compared with appropriate reference images to assure proper
positioning and the treatment couch is automatically shifted
to the proper position. IGRT allows internal set-up parame-
ters to be established rather than traditional reliance on
external (e.g., skin) markings and is particularly beneficial in
patients where treatment set-up uncertainty based on skin
marking can result in suboptimal treatment administration.
Cone-beam CT may also facilitate adaptive radiotherapy
planning to account for changes in tumor size and shape
during therapy.
MOLECULARLY TARGETED THERAPY
In this era of molecularly targeted therapy, there is a
natural interest in studying such agents in combination with
chemoradiation in NSCLC. Two specific pathways have been
studied extensively in NSCLC, the epidermal growth factor
receptor (EGFR) pathway and the vascular endothelial
growth factor (VEGF) pathway. More than 70% of NSCLC
express EGFR by immunohistochemistry.66 In the United
States approximately 10% of NSCLC have activating muta-
tions in the EGFR tyrosine kinase domain. The majority of
patients with activating mutations achieve dramatic and du-
rable responses with EGFR TK inhibitors such as gefitinib or
erlotinib.66 Even in unselected patients with advanced
NSCLC progressing after a platinum based therapy, erlotinib
improves survival compared with placebo.67 Moreover acti-
vation of the EGFR pathway occurs in tumors in response to
radiation. Preclinical studies have demonstrated consistent
synergistic interaction between radiation therapy and EGFR
inhibitors in producing cytotoxicity.68 Inhibition of this path-
way by cetuximab during radiation therapy improves survival
when compared with radiation alone in unresectable locally
advanced squamous carcinoma of the head and neck.69 Thus
potentially two approaches can be studied, one to study
EGFR inhibitors in combination with radiation therapy (ex-
ploiting a synergistic interaction) and another to study EGFR
inhibitors after chemoradiation to eradicate residual micro-
metastatic disease.
The CALGB 30106 study stratified patients with lo-
cally advanced unresectable NSCLC into 2 groups: stratum 1
(performance status of 2 or performance status 0 or 1 with
poor risk) or stratum 2 (performance status 0 or 1).70 All
patients enrolled in this study received two cycles of chemo-
therapy with paclitaxel (200 mg/m2) and carboplatin (AUC-6)
along with gefitinib before thoracic radiation. Patients in
stratum 1 received gefitinib and thoracic radiation and pa-
tients in stratum 2 received paclitaxel (50 mg/m2 weekly) and
carboplatin (AUC-2) along with gefitinib once a day during
radiation therapy. This study enrolled 59 eligible patients
(stratum 1, 20 patients and stratum 2, 39 patients) and
reported no serious acute infield toxicities with gefitinib and
radiation therapy. Although the median survival for poor risk
patients (stratum 1) was a surprising 19 months (95% CI:
5.6–21.2 months), the median survival for the good risk
patients (stratum 2) was a disappointing 12 months (95% CI:
8.5–18.6 months). This study clearly demonstrated the feasi-
bility of administration of gefitinib in combination with
radiation or chemoradiation. A smaller phase I study from
Australia demonstrated feasibility of this combination with
radiation as well. However, the overall results of CALGB
30106 were disappointing particularly in the good risk group.
The smaller number of patients studied in the poor risk group
makes it difficult to draw any firm conclusions, and the
CALGB is planning a follow-up study that will assess the
EGFR inhibitor erlotinib concurrent with radiotherapy in
poor risk patients. However, the failure to demonstrate sur-
vival improvement with gefitinib in advanced NSCLC and its
subsequent withdrawal from the market have dampened fur-
ther enthusiasm to study this specific agent in the setting of
locally advanced NSCLC.
The role of gefitinib as a maintenance therapy after
chemotherapy and radiation and consolidation docetaxel was
studied by the SWOG investigators. SWOG 0023 random-
ized patients with locally advanced NSCLC to receive pla-
cebo or gefitinib after completing chemoradiation with cis-
platin, etoposide and radiation followed by docetaxel
consolidation therapy.20 Median overall survival for the entire
study was an encouraging 19 months but the overall survival
was strikingly superior in placebo group compared with the
group that received gefitinib with a median survival from
randomization of 35 versus 23 months respectively (p 
0.01). The treatment related toxicities were similar in both the
groups. Of 118 patients assigned to gefitinib after chemora-
diation and consolidation docetaxel, 71 patients died during
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the study period (60%), most of the deaths (86%) related to
progressive disease. On the other hand, only 54 of 125 (43%)
assigned to placebo died during the study period. The reasons
for the excessive disease related mortality in patients treated
with maintenance gefitinib is unknown presently. Therefore,
EGFR TK inhibitors should not be used in the maintenance
setting after chemoradiation outside the context of a carefully
planned clinical trial in patients with locally advanced
NSCLC.
Addition of cetuximab (an antibody to EGFR) to radi-
ation improves survival in patients with locally advanced
squamous cell cancer of the head and neck compared with
radiation alone.69 Preclinical studies have suggested up-reg-
ulation of EGFR in response to radiation injury and a syner-
gistic interaction between cetuximab and radiation.68 Recent
phase II trials conducted by RTOG and CALGB have in-
cluded an assessment of cetuximab concurrent with chemo-
radiotherapy in stage III NSCLC, and preliminary results of
these studies should be available in the near future.71,72
Angiogenesis is a critical component of malignancy.
VEGF plays a crucial role in tumor angiogenesis.73 Bevaci-
zumab, a monoclonal antibody to VEGF has been approved
for use in advanced NSCLC in combination with paclitaxel
and carboplatin. A phase II study of carboplatin, irinotecan,
thoracic radiation, and bevacizumab in patients with limited
stage small cell lung cancer was closed prematurely follow-
ing three deaths related to bevacizumab with at least two
patients with confirmed and one presumed to have developed
tracheoesophageal fistula.74 These observations once again
emphasize the need for carefully planned and conducted
studies first to demonstrate the safety and feasibility before
proceeding with larger studies and routine clinical use.
THE PROBLEM OF BRAIN METASTASIS
Brain metastasis is a major cause of morbidity and
mortality in patients with locally advanced NSCLC. Approx-
imately one third of NSCLC patients develop brain metasta-
sis, including nearly two thirds of patients who have a
systemic relapse. Moreover, brain as the sole of site of relapse
occurs in approximately 20% of patients. An increasing
recognition of the importance of brain metastasis has paral-
leled improved outcomes for patients receiving aggressive
multimodality therapy. Intrathoracic tumor control has im-
proved with routine use of concurrent chemoradiotherapy and
the addition of surgery in select stage III patients. Likewise,
systemic chemotherapy seems to reduce the appearance of
distant relapse, but initial brain relapse rates have been
increasing.75,76 For example, the brain was a major site of
relapse in the landmark phase III trials, from the RTOG and
the West Japan Cancer Group, that demonstrated improved
survival for patients receiving concurrent radiation and che-
motherapy for stage III NSCLC compared with sequential
therapy.14 Moreover, patients receiving concurrent therapy in
the West Japan Cancer Group trial patients were at greater
risk of developing brain metastasis (19% versus 9%) as the
site of first relapse (likely relating to a reduced risk of tumor
failure in the lung and draining lymph nodes).
Attempts have been made to address the problem of
brain metastasis in locally advanced NSCLC in the past. Four
randomized phase III trials were conducted in the 1970s and
1980s to assess the role of prophylactic cranial irradiation
(PCI) in locally advanced NSCLC.77–80 Although the inci-
dence of brain metastases was reduced in the PCI arm in most
studies, there was no evidence that PCI improved overall
survival. In fact, a trial conducted by SWOG suggested
poorer overall survival inpatients assigned to receive PCI.
Few conclusions can be drawn from these studies given that
the methods of clinical staging and treatment employed are
obsolete by current standards coupled with the poor survival
for locally advanced NSCLC treated at the time. A modern
European study comparing tri-modality therapy with bi-mo-
dality therapy (surgery and postoperative radiotherapy) for
operable stage III NSCLC employed PCI on the tri-modality
arm (preoperative chemotherapy followed by chemoradio-
therapy and surgery). A recently updated report demonstrated
reduced brain metastases for patients receiving PCI, 9%
versus 27% at 5 years, although the trial was prematurely
closed because of slow accrual. The above data led in part to
a renewed interest in evaluating the role of PCI in locally
advanced NSCLC, and a large phase III study was undertaken
by the RTOG. RTOG 0214 randomized locally advanced
NSCLC patients to either PCI or observation following de-
finitive systemic and local therapy. Unfortunately, the trial
was closed in summer 2007 because of not meeting it accrual
goals. Thus, there is insufficient evidence to recommend PCI
outside of a clinical study.
COMPLICATIONS OF THERAPY
The 3D-chemoradiotherapy era has facilitated an as-
sessment of dose-volume relationships with regard to thoracic
radiotherapy induced toxicity. Early reports of pulmonary
toxicity related to patients treated with radiotherapy alone
(Fig. 1). A systematic review of the literature found that an
ideal dose-volume parameter predicting pulmonary toxicity
has not been identified,81 although the most widely used
measures are the volume of total lung receiving at least 20 Gy
(e.g., V20) and the mean lung dose.31,82,83 Other metrics have
also been used and it is likely that multiple physical and
biologic factors are important in predicting the risk of pul-
FIGURE 1. Lung fibrosis after radiation.
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monary toxicity. Barriers to accurately describing the rela-
tionship between treatment and its resultant toxicity include
the usage of imperfect metrics and the inaccurate reporting of
toxic effects. This may be particularly relevant for patients
with underlying pulmonary toxicity, where it may be difficult
to determine whether a functional decline is attributable to the
effects of therapy. The dose-volume relationship may also be
affected by the integration of systemic chemotherapy, and the
sequencing of therapies may significantly impact the toxic
effects of therapy. For example, in the LAMP study, patients
receiving immediate concurrent thoracic radiotherapy and
chemotherapy had a higher rate (16%) of grade 3 pulmo-
nary toxicity than patients treated with alternate sequencing.22
Nevertheless, most current prospective combined modality
trials have adopted V20 as a treatment planning parameter
and limit the V20 to a maximum 30 to 40% of the total lung
volume, although obviously a more restrictive V20 could lead
to selection of a more favorable patient population. CALGB
30105 did not include V20 as a planning parameter and a post
hoc evaluation showed a correlation between grade 3 to 5
pulmonary toxicity and V20 more than 38%, which was most
pronounced in patients with poor baseline pulmonary func-
tion.33 Transforming growth factor beta (TGF-beta) is the
most widely studied biologic predictor of radiation induced
pulmonary toxicity and has been implicated in the develop-
ment of fibrosis after exposure to chemotherapy or radiation.
Investigators have observed a correlation between changes in
TGF-beta during therapy and the development of late toxicity
in lung cancer and other malignancies.84,85 Interestingly, two
recent reports suggest that inhibition of TGF-beta in the
preclinical setting can reduce the appearance of radiation
induced lung toxicity, and it remains to be seen whether this
work will successfully translate to the clinic.86,87
Treatment induced esophageal toxicity is generally the
major clinically relevant acute toxicity of thoracic radiother-
apy. The implementation of conformal techniques may im-
pact esophageal toxicity by markedly reducing the volume of
esophagus irradiated, particularly for patients without exten-
sive mediastinal adenopathy. The risk of radiation induced
acute esophageal toxicity varies markedly according to frac-
tionation and the integration of chemotherapy. Dosimetric
parameters that may correlate with esophageal toxicity in-
clude the length of esophagus treated to more than 40 to 50
Gy, the volume of esophagus receiving more than 50 Gy, and
the treated esophageal circumference.29,88–90 The RTOG con-
ducted a randomized trial to test the ability of amifostine to
reduce esophagitis in patients receiving hyperfractionated
radiotherapy and concurrent paclitaxel and carboplatin che-
motherapy.91 The rate of grade 3 esophagitis did not differ
between the arms, 34% versus 30%, although subjective
swallowing function was better with the addition of amifos-
tine. Amifostine was associated with higher rates of acute
nausea, vomiting, cardiovascular toxicity, and infection or
febrile neutropenia. Unfortunately, design flaws, particularly
the decision to administer amifostine in conjunction with only
40% of thoracic radiotherapy fractions, preclude a definitive
assessment of the use of amifostine in a setting of combined
therapy.
FUTURE DIRECTIONS
Several strategies are currently being evaluated to im-
prove the survival in patients with locally advanced NSCLC
(www.clinicaltrials.gov.). Based on the observations that
pemetrexed and carboplatin can be administered in systemi-
cally active doses in combination with thoracic radiation,
several phase II studies have been developed to study the role
of pemetrexed in this setting.92 A phase III study is being
planned to study this agent in locally advanced NSCLC. The
role of high dose thoracic radiation in the treatment in locally
advanced NSCLC is being addressed by the ongoing RTOG-
Intergroup study. The role of FDG PET in assessing the
response to chemoradiation is the subject of an ongoing
clinical trial led jointly by the American College of Radio-
logic Imaging Network and RTOG. Several small phase I and
II studies are exploring the feasibility and safety of adding
novel molecularly targeted drugs to chemoradiation in locally
advanced NSCLC. With careful patient selection, improved
radiotherapy techniques, better supportive care and novel
systemic therapy, the outcomes of patients with locally ad-
vanced NSCLC are likely to improve in the coming decades.
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